about
Ebola virus: A gap in drug design and discovery - experimental and computational perspective.Monoclonal antibodies for the treatment of Ebola virus disease.[Overview of the Ebola vaccines in pre-clinical and clinical development].In silico-based vaccine design against Ebola virus glycoproteinNext Steps for Ebola Vaccination: Deployment in Non-Epidemic, High-Risk Settings.Responding to ever-changing epidemiological dynamics of Ebola virus disease.Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia.Ebola vaccines in clinical trial: The promising candidates.Ebola virus disease candidate vaccines under evaluation in clinical trials.Considerations for use of Ebola vaccine during an emergency response.Algevir: An Expression System for Microalgae Based on Viral Vectors.Vesicular stomatitis virus pseudotyped with Ebola virus glycoprotein serves as a protective, non-infectious vaccine against Ebola virus challenge in mice.Ebola vaccines - Where are we?Vaccines against 'the other' Ebolavirus species.Ebola Virus Binding to Tim-1 on T Lymphocytes Induces a Cytokine Storm.Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial.Virus-Vectored Ebola Vaccines.Lessons Learned from Emergency Response Vaccination Efforts for Cholera, Typhoid, Yellow Fever, and Ebola.Single-cycle adenovirus vectors in the current vaccine landscape.DNA-launched RNA replicon vaccines induce potent anti-Ebolavirus immune responses that can be further improved by a recombinant MVA boost
P2860
Q30243938-F1C0113D-963A-4D1B-B007-13CB5F63C88EQ30245073-9F932FD4-5CE2-411F-91B7-E4D7B5AAE16FQ30245207-9D35D423-95DA-49C1-9AEB-F78A79BD4426Q30843053-7CA774A2-266F-47AE-A636-453A843DBC32Q36107075-49EC9FED-7F8E-433A-A4FC-1B2685B4C85AQ37659878-2B4EEFEE-284D-449A-8684-2737B6407DC2Q37713766-DB6AF6DD-65B8-498D-8303-65261F89E0A1Q38808678-127F2A75-CBB7-4C83-9A7D-C2985F33AC96Q38830109-091F2D0E-A400-45F6-8339-084854D839EBQ40039769-0DD922FB-9123-402F-8471-0509F02FE14CQ40048049-13DD8044-C717-4C02-B1BD-74A0E00E5109Q40052567-49B690FB-54BB-4DB5-85F3-E3A1D81AF242Q40091750-E6D27C52-95C3-4CF1-BF2B-7C9B9D5E0F45Q40112699-44793FFC-DA19-4481-A29C-A91FAEDC6580Q41676229-6644CEF2-DE70-44DE-AEE4-E8CEC1DE552AQ41922839-B6247375-96A2-45F2-9CE7-F8244DA2EDE9Q43284379-4B32AAE2-C540-48A2-AD3E-0844305002BDQ44106326-FD871468-06AA-4667-B1EA-D3EF9836F571Q47282517-B2A1A09B-A6FB-41D0-A9A3-3B4D6F311ABEQ56973287-98C97161-6070-4496-8FDE-04BC4ED2E0D1
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Clinical development of Ebola vaccines
@ast
Clinical development of Ebola vaccines
@en
Clinical development of Ebola vaccines
@nl
type
label
Clinical development of Ebola vaccines
@ast
Clinical development of Ebola vaccines
@en
Clinical development of Ebola vaccines
@nl
prefLabel
Clinical development of Ebola vaccines
@ast
Clinical development of Ebola vaccines
@en
Clinical development of Ebola vaccines
@nl
P2860
P921
P3181
P356
P1476
Clinical development of Ebola vaccines
@en
P2093
Saranya Sridhar
P2860
P304
P3181
P356
10.1177/2051013615611017
P407
P577
2015-09-01T00:00:00Z